About janux therapeutics inc - JANX
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.
JANX At a Glance
Janux Therapeutics, Inc.
10955 Vista Sorrento Parkway
San Diego, California 92130
| Phone | 1-858-751-4493 | Revenue | 10.59M | |
| Industry | Biotechnology | Net Income | -68,994,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 30.991% | |
| Fiscal Year-end | 12 / 2025 | Employees | 81 | |
| View SEC Filings |
JANX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 271.803 |
| Price to Book Ratio | 3.092 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -19.38 |
| Enterprise Value to Sales | 177.154 |
| Total Debt to Enterprise Value | 0.012 |
JANX Efficiency
| Revenue/Employee | 130,716.049 |
| Income Per Employee | -851,777.778 |
| Receivables Turnover | 0.982 |
| Total Asset Turnover | 0.015 |
JANX Liquidity
| Current Ratio | 59.205 |
| Quick Ratio | 59.205 |
| Cash Ratio | 58.719 |
JANX Profitability
| Gross Margin | 80.544 |
| Operating Margin | -933.576 |
| Pretax Margin | -651.624 |
| Net Margin | -651.624 |
| Return on Assets | -9.57 |
| Return on Equity | -10.093 |
| Return on Total Capital | -6.597 |
| Return on Invested Capital | -9.776 |
JANX Capital Structure
| Total Debt to Total Equity | 2.251 |
| Total Debt to Total Capital | 2.202 |
| Total Debt to Total Assets | 2.169 |
| Long-Term Debt to Equity | 2.08 |
| Long-Term Debt to Total Capital | 2.034 |